Cargando…

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies

SIMPLE SUMMARY: There are growing data on targeting HER2 alterations, which include gene mutations, gene amplifications, and protein overexpression, for non-small cell lung cancer (NSCLC). Currently, there are limited targeted therapies approved for NSCLC patients with HER2 alterations, and this rem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uy, Natalie F., Merkhofer, Cristina M., Baik, Christina S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454740/ https://www.ncbi.nlm.nih.gov/pubmed/36077691 http://dx.doi.org/10.3390/cancers14174155

Ejemplares similares

58. CLINICAL PRESENTATION AND IMAGING CHARACTERISTICS OF LEPTOMENINGEAL CARCINOMATOSIS (LC) IN PATIENTS WITH EGFR MUTATED NON-SMALL CELL LUNG CANCER (NSCLC)
por: Eastman, Boryana, et al.
Publicado: (2020)

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report
por: Merkhofer, Cristina M., et al.
Publicado: (2021)

HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies
por: Yu, Xin, et al.
Publicado: (2022)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
por: Han, Yanjie, et al.
Publicado: (2023)

HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
por: Vathiotis, Ioannis A., et al.
Publicado: (2021)

Her2 Activates NF-κB and Induces Invasion Through the Canonical Pathway Involving IKKα
por: Merkhofer, Evan C, et al.
Publicado: (2009)

Consensus for HER2 alterations testing in non-small-cell lung cancer
por: Ren, S., et al.
Publicado: (2022)

HER2 mutations in Chinese patients with non-small cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2016)

Emerging therapies for non-small cell lung cancer
por: Zhang, Chao, et al.
Publicado: (2019)

Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy
por: Baik, Christina S., et al.
Publicado: (2017)

Efficacy of targeted therapy in patients with HER2‐positive non‐small cell lung cancer: A systematic review and meta‐analysis
por: Wu, Hong‐Xia, et al.
Publicado: (2021)

Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations
por: Ni, Jun, et al.
Publicado: (2021)

Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review
por: Metro, Giulio, et al.
Publicado: (2020)

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
por: Riudavets, M., et al.
Publicado: (2021)

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
por: Li, Shenduo, et al.
Publicado: (2023)

Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non–Small Cell Lung Cancer
por: Jacky, Jennifer, et al.
Publicado: (2017)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

Emerging Targeted Therapies for HER2-Positive Breast Cancer
por: Mercogliano, María Florencia, et al.
Publicado: (2023)

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer
por: Jacot, W, et al.
Publicado: (2004)

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
por: Lee, Kangkook, et al.
Publicado: (2020)

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer
por: Diao, Wei-Ying, et al.
Publicado: (2021)

Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer
por: Diao, Weiying, et al.
Publicado: (2022)

Chinese expert consensus on the diagnosis and treatment of HER2‐altered non–small cell lung cancer
por: Zhang, Shirong, et al.
Publicado: (2022)

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
por: Tu, Hai‐Yan, et al.
Publicado: (2023)

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
por: Jänne, Pasi A., et al.
Publicado: (2022)

Emerging therapies for small cell lung cancer
por: Yang, Sen, et al.
Publicado: (2019)

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
por: Yuan, Min, et al.
Publicado: (2019)

Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer
por: Schaefer, Eric S, et al.
Publicado: (2016)

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
por: Cappuzzo, F, et al.
Publicado: (2005)

Vaccine Therapy in Non-Small Cell Lung Cancer
por: García-Pardo, Miguel, et al.
Publicado: (2022)

The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients
por: Calikusu, Zuleyha, et al.
Publicado: (2009)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

The efficacy of afatinib in patients with HER2 mutant non-small cell lung cancer: a meta-analysis
por: Zhou, Niya, et al.
Publicado: (2020)

Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
por: Vathiotis, Ioannis A., et al.
Publicado: (2023)

Retracted: Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer
por: Markers, Disease
Publicado: (2023)

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
por: Hirsch, F R, et al.
Publicado: (2002)

Emerging role of SIRT2 in non-small cell lung cancer
por: Zheng, Mengge, et al.
Publicado: (2021)

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
por: Le, Xiuning, et al.
Publicado: (2022)

HER3 expression and MEK activation in non-small-cell lung carcinoma
por: Manickavasagar, Thubeena, et al.
Publicado: (2021)

HER2 breast cancer therapies: a review
por: Murphy, Conleth G, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_0dvm2787kt1q641pvqr0mk581p